RxDoctor Payments Data

Andrew Briggler, MD

Hematology & Oncology · Little Rock, ARNPI 1902284326

Payments from drug & device makers

$218in general payments, 2019–2025

Across 4 payments — averaging $54.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$172
  • Pfizer$25
  • Verity Pharmaceuticals Inc.$21

What the payments were for

  • Food & beverage$2110%
  • Education$19790%

General payments by program year

22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC2$172
Pfizer1$25
Verity Pharmaceuticals Inc.1$21

How this compares

$218 in reported general payments places this provider in the 10th percentile of 92 hematology & oncology providers in Arkansas.

See all hematology & oncology providers in Arkansas

Medicare billing

Part B allowed, 2024
$3,402,814
Medicare patients
915
Services billed
134,957

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide46$789,853
Lenalidomide54$719,575
Darzalex FasproDaratumumab-Hyaluronidase-Fihj64$608,651
TecentriqAtezolizumab33$358,701
PomalystPomalidomide14$264,069
Neulasta OnproPegfilgrastim39$241,004
ProcritEpoetin Alfa88$217,574
XgevaDenosumab63$196,865
MvasiBevacizumab-Awwb30$163,499
NubeqaDarolutamide11$149,135
TrazimeraTrastuzumab-Qyyp34$144,137
TruximaRituximab-Abbs13$84,467
Lupron DepotLeuprolide Acetate11$70,339
EliquisApixaban104$63,613
XareltoRivaroxaban77$45,553

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerTrazimera, Eliquis$25$207,749138 claims
Lilly USA, LLCOlanzapine$172$36233 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 92 hematology & oncology providers in Arkansas.

Other hematology & oncology in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →